Forward Pharma A/S (NASDAQ:FWP) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Forward Pharma A/S (NASDAQ:FWP – Get Rating) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the biotechnology company’s stock.

Shares of Forward Pharma A/S stock opened at $5.35 on Monday. The business’s 50 day simple moving average is $5.60 and its two-hundred day simple moving average is $5.70. Forward Pharma A/S has a one year low of $4.85 and a one year high of $20.31.

Several institutional investors and hedge funds have recently bought and sold shares of FWP. Morgan Stanley boosted its position in shares of Forward Pharma A/S by 1.2% during the second quarter. Morgan Stanley now owns 181,799 shares of the biotechnology company’s stock valued at $1,563,000 after purchasing an additional 2,099 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of Forward Pharma A/S during the third quarter valued at approximately $105,000. Renaissance Technologies LLC bought a new stake in shares of Forward Pharma A/S during the third quarter valued at approximately $597,000. Finally, Citadel Advisors LLC bought a new stake in shares of Forward Pharma A/S during the third quarter valued at approximately $141,000. 10.41% of the stock is currently owned by hedge funds and other institutional investors.

About Forward Pharma A/S (Get Rating)

Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.

See Also